ICLR logo

ICON Public Limited Company Stock Price

NasdaqGS:ICLR Community·US$14.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author

ICLR Share Price Performance

US$187.71
-108.58 (-36.65%)
17.2% undervalued intrinsic discount
US$226.60
Fair Value
US$187.71
-108.58 (-36.65%)
22.8% undervalued intrinsic discount
US$243.00
Fair Value
Price US$187.71
AnalystHighTarget US$243.00
AnalystConsensusTarget US$215.67
AnalystLowTarget US$177.23

ICLR Community Narratives

AnalystHighTarget·
Fair Value US$226.6 17.7% undervalued intrinsic discount

Digital Innovation And Personalized Trials Will Fuel Secular Demand

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·
Fair Value US$215.67 13.5% undervalued intrinsic discount

Midsized Pharma Partnerships And AI Tools Will Streamline Operations

0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AnalystLowTarget·
Fair Value US$163.85 13.8% overvalued intrinsic discount

Margin Erosion And Geopolitical Risks Will Hinder Clinical Trials

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Recent ICLR News & Updates

After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar

Aug 20
After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 43%?

Aug 12
Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 43%?

ICON: Lower Guidance Downside And Expanded Repurchase Plan

Jul 24

What Is ICON Public Limited Company's (NASDAQ:ICLR) Share Price Doing?

Jul 14
What Is ICON Public Limited Company's (NASDAQ:ICLR) Share Price Doing?

ICON Public Limited Company Key Details

US$8.1b

Revenue

US$5.8b

Cost of Revenue

US$2.3b

Gross Profit

US$1.5b

Other Expenses

US$794.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 22, 2025
Earnings per share (EPS)
10.21
Gross Margin
28.66%
Net Profit Margin
9.82%
Debt/Equity Ratio
35.7%

ICON Public Limited Company Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with proven track record.

0 Risks
4 Rewards

About ICLR

Founded
1989
Employees
39900
CEO
Barry Balfe
WebsiteView website
www.iconplc.com

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Irish Market Performance

  • 7 Days: 0.3%
  • 3 Months: 3.5%
  • 1 Year: 21.4%
  • Year to Date: 21.3%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. As for the longer term, the market has risen 21% in the past 12 months. Looking forward, earnings are forecast to grow by 7.4% annually. Market details ›